Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katie McDaniel

Physician Assistant Oxford, MS Physician Assistant

NPI 1356808422 CMS profile 10457800

1626 Highway 30 E, Oxford, MS 38655

Open in the dashboard

General payments

$10,240

577 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katie McDaniel of Oxford, MS is reported in the CMS Open Payments database as having received $10,240 across 577 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,009 43
2024 General $2,381 113
2023 General $2,313 144
2022 General $2,753 149
2021 General $1,783 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katie McDaniel
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Katie McDaniel were reported at $1,009. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Katie McDaniel Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,783 $132 $37–$438 $132
2022 $2,753 $155 $48–$522 $149
2023 $2,313 $167 $52–$557 $160
2024 $2,381 $178 $55–$600 $164
2025 $1,009 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,212 151 payments
  2. Sun Pharmaceutical Industries Inc. $1,185 53 payments
  3. UCB, Inc. $837 53 payments
  4. Janssen Biotech, Inc. $813 47 payments
  5. Novartis Pharmaceuticals Corporation $632 54 payments
  6. Pfizer Inc. $627 39 payments
  7. Mallinckrodt Hospital Products Inc. $506 24 payments
  8. LEO Pharma Inc. $482 30 payments
  9. Genzyme Corporation $440 15 payments
  10. Regeneron Healthcare Solutions, Inc. $381 18 payments
  11. Other $2,127 93 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,645 569 payments
  2. Education $595 8 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI $1,289 91 payments
  2. DUPIXENT $866 22 payments
  3. ILUMYA $827 39 payments
  4. RINVOQ $690 44 payments
  5. TREMFYA $663 33 payments
  6. ACTHAR $506 24 payments
  7. CIBINQO $487 29 payments
  8. EUCRISA $469 33 payments
  9. ADBRY $445 28 payments
  10. Cimzia $438 33 payments
  11. Other $5,531 325 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

484

Median for Physician Assistant: 241

Drug cost

$605,102

Median for Physician Assistant: $4,110

Branded share of claims

19.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 14 $286,002
Dupixent Pen Dupilumab Brand 68 $248,336
Xeljanz Xr Tofacitinib Citrate Brand 11 $59,406
Clobetasol Propionate Generic 84 $3,490
Fluorouracil Generic 39 $2,738
Betamethasone Dipropionate Generic 26 $1,276
Ketoconazole Generic 66 $1,065
Triamcinolone Acetonide Generic 63 $810
Imiquimod Generic 26 $635
Metronidazole Generic 11 $472

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$208,312

Of which drugs: $85,694

Medicare patients

786

Average age 74

Services billed

5,282

454 women, 332 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 49%
Ischemic heart disease 30%
Diabetes 26%
Depression 19%
Atrial fibrillation 16%
Chronic kidney disease 16%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 46 243 $144

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
$306 — —
TREMFYA
$264 — —
DUPIXENT
$251 68 —
ACTHAR
$249 — —
SKYRIZI
$200 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

577 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record